## Abstract The human T‐cell lymphotropic virus type 1 (HTLV‐1) is the etiological agent of HTLV‐1‐associated myelopathy/tropical spastic paraparesis (HAM/TSP), a progressive disease causing paraparesis of the lower limbs. Only a minority of persons infected with HTLV‐1 develop HAM/TSP. Universal s
Infection of rats with HTLV-1: A small-animal model for HTLV-1 carriers
✍ Scribed by T. Suga; T. Kameyama; T. Kinoshita; K. Shimotohno; M. Matsumura; H. Tanaka; S. Kushida; Y. Ami; M. Uchida; K. Uchida; M. Miwa
- Book ID
- 102864182
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- French
- Weight
- 696 KB
- Volume
- 49
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
A human T‐cell line producing human T‐cell leukemia virus type 1 (HTLV‐1), MT‐2, was injected intravenously into female F344 rats aged 5 weeks to make HTLV‐1 carrier rats. Antibody against HTLV‐1 was detected at the 5th week after MT‐2 injection, and its titer reached a high plateau which continued from the 15th to the 27th week. The antibodies were against p 19, p24, p28 and p53 of HTLV‐1 antigens from MT‐2 cells. The gag, pX and LTR nucleotide sequences of HTLV‐1 provirus were demonstrated by using polymerase chain reaction (PCR) in the peripheral‐blood mononuclear cells of 3 rats at the 44th week and 2 at the 66th to 68th week out of 8 F344 rats injected with MT‐2 cells. Quantification of the HTLV‐1 proviral sequence revealed that 30 to 60 molecules were present in 10^5^ peripheral‐blood mononuclear cells, indicating that the rats were chronically infected with HTLV‐1. HTLV‐1‐infected rats could serve as a small‐animal model for studying the pathophysiological state of HTLV‐1 carriers and also that of HTLV‐1 infection on various HTLV‐1‐related diseases, including adult T‐cell leukemia and HTLV‐1‐associated myelopathy.
📜 SIMILAR VOLUMES
## Abstract Human T‐lymphotropic virus 1 (HTLV‐1) infection is associated with HTLV‐associated myelopathy/tropical spastic paraparesis (HAM/TSP), which affects approximately 5% of carriers. High proviral load is a risk marker for HAM/TSP, although there is an overlap of proviral load levels in peri
## Abstract The development of HTLV‐1 associated clinical manifestations, such as TSP/HAM and ATLL, occur in 2–4% of the infected population and it is still unclear why this infection remains asymptomatic in most infected carriers. Recently, it has been demonstrated that HTLV uses the Glucose trans